PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish biotechs to follow in 2022.
In addition to Minoryx Therapeutics, Oryzon Genomics, Ona Therapeutics, Aelix Therapeutics, Peptomyc, Highlight Therapeutics, Algenex, InnoUp Farma and Chemotargets, VIVEbiotech has been listed as one of the ten Spanish biotech companies to watch in 2022.
VIVEbiotech is, indeed, the only Spanish CDMO that develops and manufactures lentiviral vectors to be used in clinical trials in humans.
Many thanks to PharmaBoardroom for this recognition!
About VIVEbiotech:
Contract Development and Manufacturing Organization (CDMO) specialising in manufacturing lentiviral vectors under Good Manufacturing Practice (GMP). Specifically, they develop and manufacture lentiviral vectors for different applications such as cancer immune-cell therapy and rare diseases, among others.
